TaperCommunityTaperCommunity
Forums/Drug Profiles/

Ativan Tapering Guide

lorazepam

BenzodiazepineFDA 1977
Go to Community Forum

Boxed Warning

Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Risks of abuse, misuse, and addiction, which can lead to overdose and death. Physical dependence and life-threatening withdrawal reactions.

Overview

Lorazepam is an intermediate-acting benzodiazepine approved for anxiety disorders and as a pre-anesthetic. It has no active metabolites and is metabolized by glucuronidation, making it preferred in patients with hepatic impairment or in the elderly.

Common Doses

0.5mg, 1mg, 2mg

Formulations

Tablets: 0.5mg, 1mg, 2mg; Oral concentrate: 2mg/mL; Injection: 2mg/mL, 4mg/mL

Pregnancy

Category D (positive evidence of risk)

Mechanism of Action

Positive allosteric modulator at GABA-A receptors. Binds to the benzodiazepine site and enhances GABA-mediated chloride conductance, producing anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant effects.

Taper Notes

Medium half-life benzo. Crossover to diazepam often recommended for smoother taper. Liquid formulation available.

Hyperbolic Tapering Guidance

Ashton Manual recommends crossover to diazepam for gradual taper. Never stop abruptly — seizure risk.

Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.

Tapering Protocol

Evidence-based phased reduction schedule. Always taper under medical supervision.

PhaseDurationNotes
Crossover to diazepam (optional)2-4 weeksSome prescribers recommend converting to diazepam for a smoother taper, per the Ashton Manual.
Initial reductions2-4 weeks per stepSmall, gradual reductions. Your prescriber may recommend oral concentrate for precision.
Middle reductions2-4 monthsLorazepam's medium half-life means interdose fluctuations are possible. Your prescriber may split doses for more even coverage.
Final reductions2-4 monthsOral concentrate allows the most precise adjustments. The final stretch is the most challenging.

Withdrawal Timeline

Onset

12-24 hours after reduction (faster than Klonopin due to shorter half-life)

📈Peak Severity

3-7 days

📉Resolution

2-6 weeks for acute symptoms

⚠️Protracted Risk

Anxiety rebound, insomnia, and depersonalization may persist 3-12 months. Shorter half-life than Klonopin means somewhat faster acute resolution but protracted symptoms are similar.

Community Tips

Practical insights shared by members tapering Ativan. Not medical advice — always consult your prescriber.

  • 1Ask your prescriber about Ativan oral concentrate — it allows very precise adjustments at lower doses.
  • 2Lorazepam has no active metabolites and uses glucuronidation (not CYP enzymes), so it has fewer drug interactions than other benzos — relevant if you're on multiple medications.
  • 3Discuss dosing schedule with your prescriber — splitting doses throughout the day can help with interdose symptoms.
  • 4Many members find the diazepam crossover worthwhile despite the initial adjustment period. Discuss this option with your prescriber.

Common Withdrawal Symptoms

anxietyinsomniaseizure risktremorsweatingsensory disturbances

Interactions & Safety

Drug Interactions

  • Opioids — FDA boxed warning: concurrent use increases risk of profound sedation, respiratory depression, coma, and death
  • CNS depressants (alcohol, barbiturates, other sedatives) — additive respiratory depression
  • Probenecid and valproate may increase lorazepam levels (inhibit glucuronidation)

Food Interactions

  • Food may slow absorption rate but does not reduce total bioavailability
  • Avoid alcohol (additive CNS and respiratory depression, potentially fatal)

Contraindications

  • Acute narrow-angle glaucoma
  • Known hypersensitivity to lorazepam or other benzodiazepines
  • Intra-arterial injection (parenteral formulation)

Toxicity

CNS and respiratory depression, especially with opioids or alcohol. Physical dependence with chronic use. Abrupt discontinuation can cause seizures, psychosis, and death.

Pharmacokinetics

ADME Profile

Absorption

Well absorbed after oral administration. Bioavailability ~90%. Tmax ~2 hours. Food may slow absorption but does not reduce bioavailability.

Distribution

~1.3 L/kg

Metabolism

Hepatic via glucuronidation (UGT) to the inactive lorazepam glucuronide. Does NOT undergo CYP-mediated oxidative metabolism, making it preferred in hepatic impairment.

Elimination

Renal (~88% as glucuronide conjugate). Less than 1% excreted unchanged in urine.

Protein Binding

~85%

Clearance

~1.1 mL/min/kg

Need a clinician who understands tapering?

Browse our map of deprescribing-informed providers worldwide.

Find a Deprescriber

Other Drug Profiles

Sources & References

Ativan (lorazepam) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.

Encyclopedic & chemical databases

Neutral, high-authority entity references.

Regulatory sources

Official prescribing information and safety notices.

Peer-reviewed research

Primary literature cited in this taper guide.

Deprescribing-specific resources

Clinician-facing references on tapering protocols.

Patient-advocacy & lived-experience

Long-running communities documenting withdrawal experience.

TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.